Related Experiment Video
Updated: Apr 28, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.5K
Management of Hepatocellular Adenoma: Recent Advances
Shefali Agrawal1, Sheela Agarwal2, Thomas Arnason3
1Hepatobiliary and Pancreatic Surgery, Department of Surgical Oncology, Indraprastha Apollo Hospitals, New Delhi, India.
Summary
Hepatocellular adenoma (HCA) is a rare liver neoplasm. Management depends on subtype, sex, and tumor size, balancing risks of bleeding and malignant transformation.
Area of Science:
- Hepatology
- Oncology
- Gastroenterology
Background:
- Hepatocellular adenoma (HCA) is a rare benign liver neoplasm.
- It predominantly affects young women using oral contraceptives.
- Risks include hemorrhage (25%) and malignant transformation (5%).
Purpose of the Study:
- To review the diagnosis, classification, and management of HCA.
- To delineate risks associated with different HCA subtypes.
- To provide evidence-based recommendations for HCA treatment.
Main Methods:
- Review of current literature on HCA.
- Analysis of HCA subtypes and associated complications.
- Evaluation of diagnostic and therapeutic strategies.
Main Results:
- HCA comprises 3 subtypes: inflammatory/telangiectatic (hemorrhage risk), β-catenin-activated (malignant transformation risk), and HNF-1α-inactivated/steatotic (low complication risk).
- Magnetic resonance imaging (MRI) is key for diagnosis and subtyping.
- Resection is advised for males and females with tumors ≥5 cm; surveillance is appropriate for smaller tumors in women after stopping hormonal therapy.
Conclusions:
- HCA management requires a personalized approach based on subtype, sex, and tumor size.
- MRI is crucial for accurate diagnosis and subtyping.
- Transarterial embolization is indicated for hemorrhage; pregnancy is permissible with surveillance.
